Returning to HIV Care with Biktarvy
Part of Immune system & allergy, Infections clinical trials.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have HIV-1, confirmed by a test showing the virus or its markers.
- You previously took HIV medication for at least 30 days in a row.
- You have not taken any HIV medication (pills or shots) for at least 12 weeks.
- You are ready and interested in restarting HIV treatment.
- You weigh at least 55 pounds (25 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well women with HIV stay in care while taking the medication Biktarvy (a combination of three drugs in one pill). It aims to understand their health outcomes and support better care.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
This study looks at where HIV hides in the body (called the viral reservoir) in men whose HIV is well controlled with Biktarvy. Researchers want to see how the levels of HIV medicines in the body relate to these hidden virus cells, which may help improve future treatments.
This study tests restarting a once-daily HIV pill (containing bictegravir, emtricitabine, and tenofovir alafenamide) on the same day it is prescribed, after stopping a different type of HIV medicine. It aims to see if this safe and convenient approach works well for people like you.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.